News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • DexCom shares jumped after Q2 beat, margin improvements, raised guidance and a large share-repurchase program.
  • BioAge stock plunged about 60% after Novo Nordisk's Phase 3 ZEUS trial failed to reduce major cardiovascular events.
  • Karyopharm shares collapsed after its Phase 3 endometrial cancer trial missed the primary endpoint, prompting program cutbacks and analyst downgrades.
  • Citi reports buy-the-dip behavior into the Kospi as foreign and pension flows turn positive, supporting a 10,000 index target.
  • GAO says the $21 billion Boeing-managed B-52 modernization program is over budget, behind schedule and facing performance risks.
  • Greenland Mines says international interest surged after U.S. political remarks, advancing precious metals and rare-earth projects tied to Western supply chains.

Latest Articles

Candel Therapeutics to Present at Upcoming Investor Conferences

Candel Therapeutics to Present at Upcoming Investor Conferences

Candel Therapeutics, a clinical-stage biopharmaceutical company developing multimodal immunotherapies for cancer, announced that its CEO, Paul Peter Tak, will present at the Stifel 2026 Virtual Targeted Oncology Forum and the 2026 Jefferies Global Healthcare Conference. The company highlighted progress in its lead product candidates, including agla…

Quantum Cyber N.V. Secures Exclusive Autonomous Drone Platform as Trump Administration Seeks $55 Billion for Drone Warfare

Quantum Cyber N.V. Secures Exclusive Autonomous Drone Platform as Trump Administration Seeks $55 Billion for Drone Warfare

Quantum Cyber N.V. has entered into an exclusive IP License Agreement with BP United Inc., securing innovative autonomous drone technology to advance its Quantum-ready defense platform. This move aligns with the Trump administration's significant $55 billion budget request for drone and autonomous warfare programs, marking a historic increase and s…

Allegro MicroSystems to Present at TD Cowen’s 54th Annual Technology, Media & Telecom Conference on Wednesday, May 27, 2026

Allegro MicroSystems to Present at TD Cowen’s 54th Annual Technology, Media & Telecom Conference on Wednesday, May 27, 2026

Allegro MicroSystems, a leader in power and sensing semiconductor solutions, announced its participation in TD Cowen's 54th Annual Technology, Media & Telecom Conference on May 27, 2026. The company's EVP and CFO, Derek D'Antilio, will deliver a fireside chat, further communicating Allegro's advancements and positioning in electrification, automati…

Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center

Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center

Silexion Therapeutics announced the commencement of GMP clinical batch manufacturing for SIL204, their next-generation siRNA therapy targeting mutated KRAS in locally advanced pancreatic cancer. The company also received ethics committee approval from Tel Aviv Sourasky Medical Center to conduct a Phase 2/3 clinical trial of SIL204, marking critical…

One Stop Systems to Attend Special Operations Forces Week on May 19

One Stop Systems to Attend Special Operations Forces Week on May 19

One Stop Systems, Inc. (Nasdaq: OSS), a US-based leader in rugged high performance AI and machine learning compute solutions for edge applications, announced its participation in Special Operations Forces Week from May 19 to 21, 2026. The company will demonstrate its rugged AI compute products designed for defense applications, collaborating with i…

TTEC Digital Signs Strategic Collaboration Agreement with AWS to Accelerate Amazon Connect Adoption

TTEC Digital Signs Strategic Collaboration Agreement with AWS to Accelerate Amazon Connect Adoption

TTEC Digital has entered a strategic collaboration agreement with Amazon Web Services to enhance adoption of Amazon Connect by integrating AI-powered customer experience solutions, simplifying contact center modernization. This partnership aims to deliver intelligent self-service, agent assistance, and real-time data capabilities to organizations, …

electroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia

electroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia

electroCore announced new clinical findings published in JAMA Network Open demonstrating that adding the Quell electrical nerve stimulation device to outpatient physical therapy significantly reduces movement-evoked pain and fatigue in fibromyalgia patients, with benefits observed within 30 days and sustained up to six months.

ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial

ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial

UroGen Pharma Ltd. announced positive 36-month duration of response data from its Phase 3 ENVISION trial of ZUSDURI (mitomycin) for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The Kaplan-Meier analysis showed 64.5% of patients achieving complete response at three months remained event-free at three years,…

INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point

INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point

INmune Bio announced it as a founding member of the American Biotech Innovation Alliance (ABIA), a coalition of biotechnology companies working to develop a national strategy to maintain and extend U.S. leadership in biotech innovation. The alliance will address key industry challenges such as manufacturing capacity, early research investment, regu…

Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston

Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston

Calidi Biotherapeutics announced that Dr. Antonio F. Santidrian, CSO, will present new data at the ASGCT conference highlighting the company's proprietary RedTail virotherapy platform and lead candidate CLD-401, which targets tumors via systemic delivery and exhibits immune activating properties. The company plans to file an IND for CLD-401 by the …

LiqTech International Announces First Quarter 2026 Financial Results

LiqTech International Announces First Quarter 2026 Financial Results

LiqTech International announced its Q1 2026 financial results showing a slight decline in revenue to $4.1 million compared to the prior year, and a net loss widening to $2.7 million. The company highlighted growth in commercial pool and marine water treatment markets along with a positive outlook expecting 39% to 64% revenue growth for full-year 20…

Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

Moleculin Biotech announced that the MIRACLE trial evaluating Annamycin plus cytarabine in relapsed/refractory acute myeloid leukemia (AML) is on track for first interim unblinding of data by June 30, 2026. Preliminary blinded data from 45 patients show a complete remission rate (~30%) approximately double historical rates for cytarabine alone. Rec…